Co-treatment with grape seed extract and mesenchymal stem cells in vivo regenerated beta cells of islets of Langerhans in pancreas of type I-induced diabetic rats

dc.AffiliationOctober university for modern sciences and Arts MSA
dc.contributor.authorFarid, Alyaa
dc.contributor.authorHaridyy, Hebatallah
dc.contributor.authorAshraf, Salma
dc.contributor.authorAhmed, Selim
dc.contributor.authorSafwat, Gehan
dc.date.accessioned2022-12-24T11:24:45Z
dc.date.available2022-12-24T11:24:45Z
dc.date.issued2022-12
dc.description.abstractBackground: Nowadays, diabetes mellitus is known as a silent killer because individual is not aware that he has the disease till the development of its complications. Many researchers have studied the use of stem cells in treatment of both types of diabetes. Mesenchymal stem cells (MSCs) hold a lot of potential for regenerative therapy. MSCs migrate and home at the damaged site, where they can aid in the repair of damaged tissues and restoring their function. Oxi- dative stress and infammation represent a huge obstacle during MSCs transplantation. Therefore, the present study aimed to evaluate the role of grape seed extract (GSE) administration during MSCs transplantation in streptozotocin (STZ)-induced type I diabetes. Furthermore, testing some of GSE components [procyanidins(P)-B1 and P-C1] in con- junction with MSCs, in vivo, was performed to determine if one of them was more efective in relieving the measured attributes of diabetes more than the whole GSE. Methods: Firstly, GSE was prepared from the seeds of Muscat of Alexandria grapes and characterized to identify its phytochemical components. Experimental design was composed of control group I, untreated diabetic group II, GSE (300 mg/kg)-treated diabetic group III, MSCs (2× 106 cells/rat)-treated diabetic group IV and GSE (300 mg/kg)/MSCs (2× 106 cells/rat)-treated diabetic group V. Type I diabetes was induced in rats by intravenous injection with 65 mg/kg of STZ. Treatment started when fasting blood glucose (FBG) level was more than 200 mg/dl; GSE oral administration started in the same day after MSCs intravenous injection and continued daily for 30 consecutive days. Results: The results showed that GSE/MSCs therapy in type I-induced diabetic rats has dramatically managed homeostasis of glucose and insulin secretion; together with, improvement in levels of infammatory markers and oxidative stress. Conclusion: Co-treatment with GSE and MSCs in vivo regenerates beta cells in type I-induced diabetic rats.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=19700201524&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1186/s13287-022-03218-y
dc.identifier.otherhttps://doi.org/10.1186/s13287-022-03218-y
dc.identifier.urihttp://repository.msa.edu.eg/xmlui/handle/123456789/5295
dc.language.isoen_USen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.ispartofseriesStem Cell Research & Therapy;(2022) 13:528
dc.subjectDiabetes mellitusen_US
dc.subjectGSEen_US
dc.subjectMSCen_US
dc.subjectNF-κBen_US
dc.subjectGlucoseen_US
dc.subjectInsulinen_US
dc.titleCo-treatment with grape seed extract and mesenchymal stem cells in vivo regenerated beta cells of islets of Langerhans in pancreas of type I-induced diabetic ratsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Co-treatment_with_grape_seed_extract_and_mesenchym.pdf
Size:
3.56 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: